Dr. Gail L. Wright, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 637
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME71516
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 637
- Services billed
- 117,091
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12,240 | 11 |
| Injection, aprepitant, 1 mg | 8,840 | 22 |
| Injection, denosumab, 1 mg | 7,740 | 52 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 1,860 | 23 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,827 | 528 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,660 | 33 |
| Insertion of needle into vein for collection of blood sample | 1,485 | 505 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,288 | 405 |
| Injection, palonosetron hcl, 25 mcg | 1,120 | 29 |
| Injection, ondansetron hydrochloride, per 1 mg | 952 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 38 companies reported 128 payments worth $2,767 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $278 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $203 |
| Janssen Biotech, Inc. | $177 |
| AstraZeneca Pharmaceuticals LP | $157 |
| Merck Sharp & Dohme LLC | $141 |
| AbbVie Inc. | $134 |
| Pfizer Inc. | $125 |
| Tersera Therapeutics LLC | $125 |
| Food and Beverage | $2,767 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $1,228,719 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence
Novartis Pharmaceuticals Corporation - Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Genmab U.S., Inc. - A phase 3 randomized openlabel multicenter trial of ARV471 PF07850327 vs fulvestrant in participants with estrogen receptorpositive HER2NEGATIVE advanced breast cancer whose disease progressed after prior endocrine ba…
Pfizer Inc. - DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo Inc. · Completed · NCT03529110 - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - A phase 3, open-label, randomized study of dato-dxd versus investigators choice of chemotherapy in participants with inoperable or metastatic hormone receptor positive, HER2 negative breast cancer who have been treate…
AstraZeneca Pharmaceuticals LP - A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Terminated · NCT04752332 - A phase 2, single-arm, open-label study to evaluate the safety and eff
GlaxoSmithKline, LLC. - A randomized doubleblind phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2 breast cancer HER2CLIMB05
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.